WO2008112232A3 - Methods for monitoring gamma secretase inhibition in vivo - Google Patents

Methods for monitoring gamma secretase inhibition in vivo Download PDF

Info

Publication number
WO2008112232A3
WO2008112232A3 PCT/US2008/003238 US2008003238W WO2008112232A3 WO 2008112232 A3 WO2008112232 A3 WO 2008112232A3 US 2008003238 W US2008003238 W US 2008003238W WO 2008112232 A3 WO2008112232 A3 WO 2008112232A3
Authority
WO
WIPO (PCT)
Prior art keywords
vivo
methods
gamma secretase
inhibition
secretase
Prior art date
Application number
PCT/US2008/003238
Other languages
French (fr)
Other versions
WO2008112232A2 (en
Inventor
Viswanath Devanarayan
William Z Potter
Jacquelynn J Cook
Adam J Simon
Original Assignee
Merck & Co Inc
Viswanath Devanarayan
William Z Potter
Jacquelynn J Cook
Adam J Simon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Viswanath Devanarayan, William Z Potter, Jacquelynn J Cook, Adam J Simon filed Critical Merck & Co Inc
Publication of WO2008112232A2 publication Critical patent/WO2008112232A2/en
Publication of WO2008112232A3 publication Critical patent/WO2008112232A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present invention provides a means for monitoring the inhibition of γ secretase in an Alzheimer's disease (AD) patient or control subject in vivo using a γ secretase inhibitor biomarker. Statistically relevant biomarkers identified from a fluid sample of a patient treated with an AD therapeutic are identified and used to monitor γ secretase inhibition and the efficacy of a γ-secretase inhibitor.
PCT/US2008/003238 2007-03-13 2008-03-11 Methods for monitoring gamma secretase inhibition in vivo WO2008112232A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90668307P 2007-03-13 2007-03-13
US60/906,683 2007-03-13

Publications (2)

Publication Number Publication Date
WO2008112232A2 WO2008112232A2 (en) 2008-09-18
WO2008112232A3 true WO2008112232A3 (en) 2008-12-04

Family

ID=39760289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003238 WO2008112232A2 (en) 2007-03-13 2008-03-11 Methods for monitoring gamma secretase inhibition in vivo

Country Status (1)

Country Link
WO (1) WO2008112232A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids

Also Published As

Publication number Publication date
WO2008112232A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2010082944A3 (en) Systems and methods for imaging changes in tissue
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
IL213825A0 (en) Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
ZA200605394B (en) Device and method for rapidly determining the effectiveness of sterilization or disinfection processes
EP2200548A4 (en) Fluid flowing device and method for tissue diagnosis or therapy
GB2429013C (en) Peptides for treatment and diagnosis of autoimmunedisease
IL186824A0 (en) Apparatus and methods for the destruction of adipose tissue
WO2007101190A3 (en) Clinical applications of sto2 analysis
ZA201000847B (en) Device and procedure for the diagnosis or diagnostic preparation and/or therapy monitoring of inflammatory disease such as rheumatoid arthritis
WO2010059242A3 (en) Neurodegenerative disease diagnostic compositions and methods of use
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
WO2006133287A3 (en) Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
WO2007126391A8 (en) Investigation of mucosa dryness conditions
EP1863940A4 (en) Method of risk management for patients undergoing natalizumab treatment
MX2007003518A (en) Metalloproteinase inhibitor imaging agents.
WO2012065045A3 (en) Development and screening of contrast agents for in vivo imagining of parkinson's disease
MY155340A (en) Use of cathepsin c
EP2134863A4 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2009089521A3 (en) Predictors for evaluating response to cancer therapy
EP1954832A4 (en) Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
WO2008008487A3 (en) Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
WO2008112232A3 (en) Methods for monitoring gamma secretase inhibition in vivo
EP1916943A4 (en) System and method for assessing cognitive function and measuring treatment efficacy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08726724

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08726724

Country of ref document: EP

Kind code of ref document: A2